Roche Wins Safe Harbor For Mircera Tests — For Now

Law360, New York (April 30, 2009, 12:00 AM EDT) -- An appeals court has ruled that Swiss pharmaceutical giant Roche Holding Ltd. can continue to develop anemia drug Mircera using processes allegedly patented by Amgen Inc. pending a closer look by the U.S. International Trade Commission at whether Roche's activities violated statutory exemption rules.

The U.S. Court of Appeals for the Federal Circuit issued an en banc ruling affirming an ITC decision to allow Roche safe harbor for importing certain recombinant human erythropoietin and derivatives allegedly made through processes covered by U.S. patents held by rival...
To view the full article, register now.